Krystal Biotech reports FY2021 net loss $69.6M, cash $502.5M; on track for Vyjuvek BLA in 1H 2022

Krystal Biotech, Inc.

2021-FY EPS reported -$3.13

Net loss Q4 2021 $21.8M ($0.94/share); full year $69.6M ($3.13/share) vs. $32.2M ($1.71) in 2020.
Cash & equivalents $502.5M at Dec 31, 2021, up from $271.3M; net proceeds from public offerings.
Positive Phase 3 GEM-3 data for Vyjuvek (DEB); BLA filing expected 1H 2022, MAA in 2H 2022.
Phase 1 trial of KB407 for cystic fibrosis expected to start in Australia 1H 2022; US trial in 2H 2022.
Suma Krishnan promoted to President R&D effective Feb 25, 2022; she was COO and founder.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Suma M. Krishnan

President, R&D

KRYS · Krystal Biotech, Inc.

Effective: 2022-02-25
Filed: February 28, 2022, 6:59 PM ET

Effective February 25, 2022, the board of directors of the Company appointed Ms. Suma M. Krishnan, the Company's current Chief Operating Officer, as the Company's President, R&D.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Suma M. Krishnan was appointed as President, R&D at Krystal Biotech, Inc..

Action: appointed
Role: President, R&D

Exact text from the filing

Effective February 25, 2022, the board of directors of the Company appointed Ms. Suma M. Krishnan, the Company's current Chief Operating Officer, as the Company's President, R&D.

View on SEC.gov

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-22-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.